The Cardiovascular and Hematological Risks of Testosterone Replacement Therapy for Age-Related Hypogonadism

When exogenous testosterone enters the bloodstream, it binds to androgen receptors in the bone marrow and kidneys, stimulating the production of erythropoietin and directly driving the synthesis of new red blood cells. This specific biological step—erythropoiesis—is where the cardiovascular safety of testosterone replacement therapy is actually determined. For decades, patients and physicians have debated whether testosterone itself damages the heart, but recent clinical data reveals that the hormone is largely a bystander. The true driver of cardiovascular risk is the physical crowding of the bloodstream, a condition known as secondary polycythemia.[2][5]

Understanding this mechanism fundamentally changes how testosterone therapy should be managed. If the hormone inherently caused heart attacks, the only safe option would be to avoid it entirely. However, because the risk is mediated by the volume of red blood cells—measured clinically as hematocrit—the danger can be monitored, quantified, and controlled. For men treating age-related hypogonadism, this means cardiovascular safety is not a guessing game; it is a direct function of routine blood work and dosage management.[2][5]

The historical context of testosterone and heart health has been fraught with conflicting data and regulatory warnings. Early observational studies in the Veterans Affairs health system suggested an association between testosterone use and adverse cardiovascular outcomes, prompting widespread hesitation among both patients and prescribers. In 2015, regulatory agencies required warning labels on testosterone products regarding potential cardiovascular risks. However, the medical consensus began to shift as larger, more rigorous trials were completed, culminating in a reevaluation of how testosterone interacts with the vascular system.[1][4]

The clearest evidence exonerating testosterone itself comes from the recent TRAVERSE trial, a landmark study involving over 5,200 men with hypogonadism and elevated cardiovascular risk. The trial demonstrated that testosterone replacement therapy did not increase the overall incidence of major adverse cardiovascular events compared to a placebo. Consequently, regulatory guidance has been updated to reflect this safety profile. Yet, while the hormone passed the safety test, the secondary effects it triggers in the blood did not.[4][5]

This is where the distinction between the hormone and the hematocrit becomes critical. A comprehensive review published in the Journal of Urology analyzed a database of over 74 million patients to isolate the effects of testosterone-induced polycythemia. The researchers compared 5,842 testosterone-treated men who developed a hematocrit above 52% against a matched cohort of 5,842 men whose hematocrit remained in the normal range. The findings isolated the exact mechanism of harm: the men who developed secondary polycythemia experienced a significantly higher rate of cardiovascular and thromboembolic events in their first year of therapy.[3]

The data provides a precise quantification of this risk. In the matched cohorts, the incidence of major adverse cardiovascular events or venous thromboembolism was 5.15% in the polycythemia group, compared to 3.87% in the normal hematocrit group. This translates to a 35% relative increase in risk purely driven by the thickening of the blood. When red blood cell volume exceeds the 52% threshold, blood viscosity increases, forcing the heart to pump harder and creating an environment where clots are more likely to form in the deep veins or coronary arteries.[3][5]

The timing of these events offers further practical guidance for patients. The spike in cardiovascular risk is most pronounced during the first 12 months of testosterone therapy, aligning with the period when hematocrit levels typically peak. As the body adjusts to the exogenous hormone, the bone marrow's red blood cell production accelerates rapidly. If a patient is going to develop secondary polycythemia, it almost always occurs within this initial window, making early and frequent blood monitoring the most effective preventative measure.[2][3]

Different delivery methods of testosterone exert varying degrees of stress on the bone marrow. Intramuscular injections, particularly those administered every few weeks, create sharp peaks and troughs in serum testosterone levels. These supraphysiological spikes provide a strong, intermittent stimulus for erythropoiesis, resulting in the highest rates of secondary polycythemia. In contrast, transdermal gels, patches, and daily oral formulations deliver a steady, continuous dose that mimics the body's natural circadian rhythm, significantly reducing the overproduction of red blood cells.[2][4]

For patients currently on testosterone therapy, these findings translate into a clear, actionable protocol. A baseline hematocrit must be established before treatment begins, followed by follow-up blood tests at three months, six months, and annually thereafter. If the hematocrit approaches the 52% threshold, the risk of a cardiovascular event begins to outweigh the benefits of the therapy. At this point, clinical intervention is required to thin the blood and reduce vascular strain.[3][5]

Managing an elevated hematocrit does not necessarily mean abandoning testosterone therapy. The most immediate solution is therapeutic phlebotomy—the medical removal of blood—which rapidly lowers red blood cell volume and restores normal viscosity. However, to prevent the hematocrit from rebounding, physicians will typically adjust the treatment regimen. This may involve lowering the weekly dosage, increasing the frequency of injections to smooth out serum peaks, or switching from an injectable ester to a topical gel.[2][5]

It is also crucial to identify compounding factors that drive up red blood cell counts independently of testosterone. Untreated obstructive sleep apnea is a primary culprit; the chronic oxygen deprivation experienced during sleep signals the kidneys to produce more erythropoietin, compounding the effects of the testosterone therapy. Smoking similarly reduces blood oxygenation, forcing the body to compensate by generating more red blood cells. Addressing these underlying issues is often necessary to keep hematocrit levels safely below the danger zone.[2][5]

Ultimately, the narrative surrounding testosterone replacement therapy has evolved from broad cardiovascular fear to precise hematological management. The hormone itself, when restoring deficient levels to a physiological baseline, does not damage the heart. The danger lies entirely in the dose-dependent overproduction of red blood cells. By treating hematocrit as a vital sign—monitoring it closely and intervening when it rises—patients can safely realize the metabolic and psychological benefits of testosterone therapy without compromising their cardiovascular health.[3][5]